Predicting endocrine responsiveness: novel biomarkers on the horizon

Oncology (Williston Park). 2009 Feb;23(2):154, 156, 159.

Authors

Kimberly F Kerstann¹, Mark Bouzyk, Mark Abramovitz, Brian Leyland-Jones

Affiliation

¹ Center for Medical Genomics, Winship Cancer Institute, Emory University, USA.

PMID: 19323296

No abstract available

Publication types

Comment

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use*
Aromatase Inhibitors / therapeutic use
Biomarkers, Tumor / genetics*
Breast Neoplasms / drug therapy*
Breast Neoplasms / genetics*
Chemotherapy, Adjuvant / methods
Female
Humans
Oligonucleotide Array Sequence Analysis / methods
Pharmacogenetics*
Prognosis
Receptor, ErbB-2 / genetics
Receptors, Estrogen / genetics
Selective Estrogen Receptor Modulators / therapeutic use

Substances

Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Biomarkers, Tumor
Receptors, Estrogen
Selective Estrogen Receptor Modulators
Receptor, ErbB-2